AB
SYRE icon

Amalgamated Bank’s Spyre Therapeutics SYRE Stock Holding History

Amalgamated Bank’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,165
Closed -$71K – 2685
2025
Q4 		$71K Buy
2,165
+786
+57% +$20.5K ﹤0.01% 1753
2025
Q3 		$23K Hold
1,379
– – ﹤0.01% 2071
2025
Q2 		$21K Hold
1,379
– – ﹤0.01% 2101
2025
Q1 		$22K Buy
1,379
+181
+15% +$3.77K ﹤0.01% 2034
2024
Q4 		$28K Hold
1,198
– – ﹤0.01% 2006
2024
Q3 		$35K Hold
1,198
– – ﹤0.01% 1953
2024
Q2 		$28K Buy
+1,198
New +$40.4K ﹤0.01% 2010
2022
Q2 		– Sell
-195
Closed -$11K – 3193
2022
Q1 		$11K Buy
+195
New +$16.4K ﹤0.01% 2946

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Amalgamated Bank's SYRE Position: Q1 2026 in Review

Amalgamated Bank sold out of Spyre Therapeutics (SYRE) in Q1 2026, closing a stake of 2,165 shares — an estimated $71K sold.

Amalgamated Bank first reported a position in SYRE in Q1 2022 and held it in 8 quarters. The position peaked at $71K in Q4 2025. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Amalgamated Bank reported no remaining Spyre Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,165 Spyre Therapeutics shares in Q1 2026, an estimated $71K.
  • Amalgamated Bank first reported a position in Spyre Therapeutics in Q1 2022 and held it in 8 quarters.
  • Amalgamated Bank's Spyre Therapeutics position peaked at $71K in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.